Skip to main content
Equibles
ALEC logo

ALEC · Alector, Inc.

Track ALEC — free

Use ALEC with AI

Ask our own analyst here, or connect this data to the AI you already use.

Ask ALVIS about ALEC

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

or use your own AI

The free Equibles MCP server lets any client query SEC filings, earnings calls, KPIs, holdings and prices directly — read-only, OAuth-secured, cited to the filing.

ChatGPT Claude Gemini
Server URL
https://mcp.equibles.com/mcp
All connection guides →
$2.39 -0.07 (-2.85%) At close · Aug 27
Market Cap
$274.68M
Shares
111.66M

Price & Indicators

Indicators
Price
Panels
Event markers
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$2.39 Open$2.44 Day$2.39–2.50 52W close$1.14–3.32 Avg vol 30d1.2M Short int5.9M · 5.3% float · 3.5d Short vol55% Last earningsAug 7, 2025 DataJan 2020–Aug 2026 Filing10-Q · Aug 6

Up next

FQ3-26 quarter ends
~Sep 30, 2026 Est
Latest filing: 10-Q
filed Aug 6, 2026

Equibles Rating

blended score · not investment advice
Overall
Neutral
SellHoldBuy
Technical Buy Momentum Very Strong Sentiment Neutral Fundamentals Weak Quant / Vol Very High
Market backdrop VIX 14.5 · calm Equity put/call 0.39
Technical
price trend
Buy
50 / 200-day cross No cross
Price vs 200-day avg +27%
above
Price vs 50-day avg +31%
above
RSI (14) 64
neutral
MACD trend Positive
52-week position 57%
mid-range
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Strong
1-month return +48%
trailing
6-month return +20%
trailing
YTD return +53%
this year
Relative strength +5%
vs S&P · 6-mo
Sentiment
smart money
Neutral
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +14 funds added
Insider flow Distributing
Net -$228.2K over 90 days · 100% sells
Short interest Rising
5.29% of float · ▲ +4.6% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
141 holders — mid 3-yr range
Squeeze score 61
elevated · 0–100
Fundamentals
Weak
Revenue growth −79%
Y/Y
EPS growth −13%
Y/Y
Free cash flow $-184.1M
Balance sheet $56.1M
net cash
Quant / Vol
risk profile
Very High
Volatility 95%
annualized · 1-yr
Max drawdown −66%
past year
ATR 8.1%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

Latest guidance · from the 8-K filed Oct 21, 2025
Total incremental restructuring charges associated with the redu · first half of 2026 Initiated $7.7M
Prior guidance period ended · from the 8-K filed Nov 6, 2025
Collaboration revenue · 2025 $13M – $18M
Total research and development expenses · 2025 $130M – $140M
Total general and administrative expenses · 2025 $55M – $65M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Buy
0 · 4 · 3
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
+27% Bullish
Price vs 50-day avg
+31% Bullish
RSI (14)
64 Neutral
MACD trend
Positive Bullish
52-week position
57% Neutral
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bearish · 2 of 6
Trend (MA cross) No cross
50d $2 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+2% holders QoQ · +14 funds added
Insider flow Distributing
Net -$228.2K over 90 days · 100% sells
Short interest Rising
5.29% of float · ▲ +4.6% MoM · 3.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Steady
141 holders — mid 3-yr range
Price context
position in its 52-week range
Range low $1 Now $2 · 57% Range high $3
vs 200-day avg +27% vs 50-day avg +31%

Illustrative technical + ownership context — a signal mix, not investment advice.

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
ALEC
Alector, Inc.
this stock
$274.68M +53.2% -79.1% — 5.3%
VRTX
Vertex Pharmaceuticals Inc / Ma
 $138.72B +20.8% +46.2% 31.9 1.6%
REGN
Regeneron Pharmaceuticals, Inc.
 $83.89B +4.6% +20.8% 20.2 2.3%
ARGX
Argenx SE
 $65.12B +25.9% — — 1.9%
CSLLY
Csl Ltd
 $59.92B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
141
% held
82.5%
Net QoQ
+3.5M sh
Top holder
TCG Crossover Management,…
Held Float
View
Held by Funds
Fund positions
136
View
Short & Settlement
Short Interest Rising
Shares short
5.9M
Days to cover
3.5d
Change
+257.3K sh
View
Short Volume
Short vol %
55%
As of
Aug 27, 2026
Short Total
View
Fails to Deliver
FTD shares
5.1K
Value
$7.7K
As of
Jul 29, 2026
View
Off-Exchange
Off-exchange %
31.7%
Week of
Jul 20, 2026
Off-exch Lit
View
Smart Money
Insider Trades Net selling
Net (90d)
-$228.2K
Buyers / Sellers
0 / 3
Buyers Sellers
View
Financials
Financials
Revenue (FY)
$21.0M
Net income (FY)
$-142.9M
EPS diluted
$-1.39
View
Filings
SEC Filings
Latest
8-K
Filed
Aug 6, 2026
This year
10
View
Proposed Sales
Value
$6.5K
Shares
3.5K
Filed
Jun 3, 2026
View
Earnings & Events
Earnings Calls
Last call
Aug 7, 2025
View

Performance

5D 20D 120D MTD YTD
ALEC +5.8% +47.5% +19.5% +58.3% +53.2%
SPY +1.1% +4.0% +14.7% +3.2% +13.1%
vs SPY +4.6% +43.6% +4.8% +55.1% +40.1%
Key facts CIK 1653087 CUSIP 014442107 13F (30d) 123 filings 123 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)